Methods: A retrospective cohort study was conducted on patients admitted to the Pediatric Endocrinology Departments of two centers in Turkey. Girls treated with GnRH analogs between March 2018 and 2022 were categorized into two groups: the pre-pandemic group (2018-2020) and the pandemic group (2020-2022). Clinical, anthropometric, and hormonal data were analyzed. Patients with organic lesions, genetic conditions, or medications affecting puberty were excluded.
